Cargando…

Treatment decisions in advanced ovarian cancer.

Detalles Bibliográficos
Autores principales:	Cody, M. M., Slevin, M. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247045/ https://www.ncbi.nlm.nih.gov/pubmed/2669920

Ejemplares similares

Geographical epidemiology of ovarian and testicular germ cell cancers.
por: Kamdar, R. H., et al.
Publicado: (1998)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
por: Malik, S. T., et al.
Publicado: (1991)

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.
por: Osborne, R. J., et al.
Publicado: (1988)

The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.
por: Thompson, P., et al.
Publicado: (1991)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

A study to investigate the incidence of early satiety in patients with advanced cancer.
por: Armes, P. J., et al.
Publicado: (1992)

Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision
por: Sowerbutts, Anne Marie, et al.
Publicado: (2020)

Phase II trial of UFT in advanced colorectal and gastric cancer.
por: Malik, S. T., et al.
Publicado: (1990)

Advances in ovarian cancer therapy
por: Cortez, Alexander J., et al.
Publicado: (2017)

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994)

The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer
por: Walraven, Janneke E.W., et al.
Publicado: (2022)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
por: Hopkins, M.L., et al.
Publicado: (2007)

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015)

Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer?
por: Pereira, Augusto, et al.
Publicado: (2022)

Improving ovarian cancer treatment decision using a novel risk predictive tool
por: Xu, Zhenyi, et al.
Publicado: (2022)

Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.
por: Peppercorn, P. D., et al.
Publicado: (1998)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.
Publicado: (1990)

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.
por: Bronchud, M. H., et al.
Publicado: (1989)

The prognostic value of morphometry in advanced epithelial ovarian cancers.
por: Katsoulis, M., et al.
Publicado: (1995)

Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer
por: Kim, Se Ik, et al.
Publicado: (2014)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
por: Mainwaring, P. N., et al.
Publicado: (1997)

Advanced directives and treatment decisions in the intensive care unit
por: Whetstine, Leslie M
Publicado: (2007)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

Emotional support for cancer patients: what do patients really want?
por: Slevin, M. L., et al.
Publicado: (1996)

Patients' Preferences for Participation in Treatment Decision-Making at the End of Life: Qualitative Interviews with Advanced Cancer Patients
por: Brom, Linda, et al.
Publicado: (2014)

Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
por: Gore, M. E., et al.
Publicado: (1997)

Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data
por: Vlahou, Antonia, et al.
Publicado: (2003)

Dose intensity analysis in advanced ovarian cancer patients.
por: Torri, V., et al.
Publicado: (1993)

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
por: Aabo, K., et al.
Publicado: (1998)

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
por: Kurnit, Katherine C., et al.
Publicado: (2021)

Advances of exosomal miRNAs in the diagnosis and treatment of ovarian cancer
por: Xiong, Jun, et al.
Publicado: (2023)

The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer
por: Chen, Biqing, et al.
Publicado: (2023)

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

Patient, physician, and caregiver perspectives on ovarian cancer treatment decision making: lessons from a qualitative pilot study
por: Pozzar, Rachel, et al.
Publicado: (2018)

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
por: Kubelac, Paul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g2342uecftboo6lq496qd31vs1